PDE4A and psoriasis vulgaris: With evidence from randomized controlled trials (RCTs), we aimed to perform a network meta-analysis (NMA) to assess the efficacy and safety of oral PDE4 and TYK2 inhibitors in treating moderate-to-severe plaque psoriasis.